ClinicalTrials.gg
CompletedNCT00643136Updated Apr 24, 2008

A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures

A Phase 3 interventional study of Pregabalin and Placebo in Sleep Deprivation and Epilepsies, Partial, sponsored by Pfizer. Completed at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the effects of pregabalin on sleep problems in patients with seizures.

02

Conditions studied

  • Sleep Deprivation
  • Epilepsies, Partial
03

In context

Sleep Deprivation

314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.

This study's enrollment of 17 is below the median of 50 across 259 interventional studies indexed under Sleep Deprivation.

Browse Sleep Deprivation studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Partial epileptic seizures
  • Not taking more than 1 background antiepileptic drug at study entry
  • Disturbed sleep

Exclusion criteria

Exclusion Criteria:

  • More than 1 secondarily generalized tonic/clonic seizure per week on average over the previous 3 months
  • Medical, psychological, or social conditions that could interfere with normal sleep
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Drug: Pregabalin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28

  • DrugPlacebo

    Matching placebo capsules twice daily for 28 days

06

What researchers measure

Primary outcomes

  1. Change from baseline in polysomnographic (PSG) sleep efficiency in the efficacy evaluable population

    Time frame: Endpoint

Secondary outcomes

  1. Change from baseline in total sleep time

    Time frame: Endpoint

  2. Change from baseline in sleep onset latency

    Time frame: Endpoint

  3. Change from baseline in wake after sleep onset

    Time frame: Endpoint

  4. Change from baseline in percent sleep spent in stages 3 and 4

    Time frame: Endpoint

  5. Change from baseline in percent sleep spent in REM stage

    Time frame: Endpoint

  6. Change from baseline in night sleep quality based on Groningen Sleep Questionnaire (GSQ)

    Time frame: Endpoint

  7. Change from baseline in 4-week sleep quality (Medical Outcomes Study [MOS] Sleep Scale)

    Time frame: Endpoint

  8. Adverse events and laboratory value changes

    Time frame: Endpoint

07

Study locations

2 sites
  • Pfizer Investigational Site
    Den Haag, 2501 CK, Netherlands
  • Pfizer Investigational Site
    Heeze, 5591 VE, Netherlands
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 26, 2008
Start
Nov 2002
CompletionActual
Jun 2004
Last update
Apr 24, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00643136
Lead sponsor
Pfizer
First posted
Mar 26, 2008
Start date
Nov 2002
Completion
Jun 2004
Last update
Apr 24, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion